[go: up one dir, main page]

US3898339A - Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin - Google Patents

Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin Download PDF

Info

Publication number
US3898339A
US3898339A US388147A US38814773A US3898339A US 3898339 A US3898339 A US 3898339A US 388147 A US388147 A US 388147A US 38814773 A US38814773 A US 38814773A US 3898339 A US3898339 A US 3898339A
Authority
US
United States
Prior art keywords
tetrodotoxin
desoxytetrodotoxin
micrograms
anesthesia
spinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US388147A
Other languages
English (en)
Inventor
Herbert J F Adams
Jr Murray R Blair
Robert N Boyes
Maxim I Lebeaux
Helen G Vassall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astra USA Inc
Original Assignee
Astra Pharmaceutical Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharmaceutical Products Inc filed Critical Astra Pharmaceutical Products Inc
Priority to US388147A priority Critical patent/US3898339A/en
Priority to SE7311340A priority patent/SE7311340L/xx
Priority to FI2638/73A priority patent/FI263873A7/fi
Priority to NO3357/73A priority patent/NO335773L/no
Priority to DK470273*A priority patent/DK470273A/da
Priority to NO742001A priority patent/NO742001L/no
Priority to DE19742427732 priority patent/DE2427732A1/de
Priority to AU69934/74A priority patent/AU489490B2/en
Priority to IE1211/74A priority patent/IE39410B1/xx
Priority to ES427164A priority patent/ES427164A1/es
Priority to FR7420219A priority patent/FR2240735B1/fr
Priority to LU70304A priority patent/LU70304A1/xx
Priority to AT484974A priority patent/AT335616B/de
Priority to BE145320A priority patent/BE816214A/fr
Priority to ZA00743765A priority patent/ZA743765B/xx
Priority to DD179117A priority patent/DD115035A5/xx
Priority to JP49067020A priority patent/JPS5048112A/ja
Priority to GB2609474A priority patent/GB1453343A/en
Priority to NL7407853A priority patent/NL7407853A/xx
Priority to CA202,294A priority patent/CA1027863A/fr
Priority to NO750209A priority patent/NO750209L/no
Application granted granted Critical
Publication of US3898339A publication Critical patent/US3898339A/en
Priority to SE7605006A priority patent/SE7605006L/xx
Priority to NO772984A priority patent/NO772984L/no
Priority to FI772889A priority patent/FI772889A7/fi
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US388147A 1973-06-12 1973-08-14 Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin Expired - Lifetime US3898339A (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
US388147A US3898339A (en) 1973-08-14 1973-08-14 Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin
SE7311340A SE7311340L (fr) 1973-06-12 1973-08-21
FI2638/73A FI263873A7 (fr) 1973-06-12 1973-08-23
NO3357/73A NO335773L (fr) 1973-06-12 1973-08-24
DK470273*A DK470273A (fr) 1973-06-12 1973-08-27
NO742001A NO742001L (fr) 1973-06-12 1974-06-04
DE19742427732 DE2427732A1 (de) 1973-08-14 1974-06-08 Mittel zum anaesthesieren von saeugetieren
AU69934/74A AU489490B2 (en) 1974-06-10 I. anesthetic COMPOSITION AND METHOD
IE1211/74A IE39410B1 (en) 1973-08-14 1974-06-10 Anesthetic compositions and their use
FR7420219A FR2240735B1 (fr) 1973-08-14 1974-06-11
ES427164A ES427164A1 (es) 1973-08-14 1974-06-11 Un procedimiento para la preparacion de un agente para la anastesia espinal.
BE145320A BE816214A (fr) 1973-08-14 1974-06-12 Nouvelles compositions therapeutiques
LU70304A LU70304A1 (fr) 1973-08-14 1974-06-12
ZA00743765A ZA743765B (en) 1973-08-14 1974-06-12 New therapeutical compositions
DD179117A DD115035A5 (fr) 1973-08-14 1974-06-12
JP49067020A JPS5048112A (fr) 1973-08-14 1974-06-12
GB2609474A GB1453343A (en) 1973-08-14 1974-06-12 Anaesthetic compositions and their use
NL7407853A NL7407853A (nl) 1973-08-14 1974-06-12 Werkwijze voor het bereiden van anesthetisch werkzame preparaten.
CA202,294A CA1027863A (fr) 1973-08-14 1974-06-12 Composes therapeutiques
AT484974A AT335616B (de) 1973-08-14 1974-06-12 Verfahren zur herstellung eines mittels fur die spinalanasthesie
NO750209A NO750209L (fr) 1973-06-12 1975-01-23
SE7605006A SE7605006L (sv) 1973-06-12 1976-04-30 Farmaceutika
NO772984A NO772984L (no) 1973-06-12 1977-08-29 Farmas¦ytika.
FI772889A FI772889A7 (fr) 1973-06-12 1977-09-30

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US388147A US3898339A (en) 1973-08-14 1973-08-14 Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin

Publications (1)

Publication Number Publication Date
US3898339A true US3898339A (en) 1975-08-05

Family

ID=23532901

Family Applications (1)

Application Number Title Priority Date Filing Date
US388147A Expired - Lifetime US3898339A (en) 1973-06-12 1973-08-14 Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin

Country Status (14)

Country Link
US (1) US3898339A (fr)
JP (1) JPS5048112A (fr)
AT (1) AT335616B (fr)
BE (1) BE816214A (fr)
CA (1) CA1027863A (fr)
DD (1) DD115035A5 (fr)
DE (1) DE2427732A1 (fr)
ES (1) ES427164A1 (fr)
FR (1) FR2240735B1 (fr)
GB (1) GB1453343A (fr)
IE (1) IE39410B1 (fr)
LU (1) LU70304A1 (fr)
NL (1) NL7407853A (fr)
ZA (1) ZA743765B (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024903A1 (fr) * 1994-03-17 1995-09-21 Nanning Maple Leaf Pharmaceutical Co., Ltd. Application de composes de quinazoline amino-hydrogenes et de leurs derives au sevrage des toxicomanes
WO1996014860A1 (fr) * 1994-11-10 1996-05-23 Merck & Co., Inc. PROCEDE POUR IDENTIFIER LES MODULATEURS DE CANAUX CATIONIQUES $i(PARA)
US5585398A (en) * 1994-07-15 1996-12-17 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
CN1051706C (zh) * 1994-03-17 2000-04-26 南宁枫叶药业有限公司 氨基氢化喹唑啉类化合物及其衍生物戒降药物依赖性的新用途
WO2002041915A1 (fr) * 2000-11-22 2002-05-30 Nanning Maple Leaf Pharmaceutical Co., Ltd. Composition de compose bloquant les canaux sodiques
US20100048592A1 (en) * 2005-08-25 2010-02-25 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the management of musculoskeletal pain
US20100075992A1 (en) * 2004-09-22 2010-03-25 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain
US20100215771A1 (en) * 2006-03-27 2010-08-26 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, Vol. 77 (1972), p. 168634y. *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1051706C (zh) * 1994-03-17 2000-04-26 南宁枫叶药业有限公司 氨基氢化喹唑啉类化合物及其衍生物戒降药物依赖性的新用途
WO1995024903A1 (fr) * 1994-03-17 1995-09-21 Nanning Maple Leaf Pharmaceutical Co., Ltd. Application de composes de quinazoline amino-hydrogenes et de leurs derives au sevrage des toxicomanes
US5846975A (en) * 1994-03-17 1998-12-08 Nanning Maple Leaf Pharmaceutical Co., Ltd. Use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
US5585398A (en) * 1994-07-15 1996-12-17 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
US5942543A (en) * 1994-07-15 1999-08-24 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
US7001734B1 (en) 1994-11-10 2006-02-21 Merck & Co., Inc. Process for identifying para cation channel modulators
WO1996014860A1 (fr) * 1994-11-10 1996-05-23 Merck & Co., Inc. PROCEDE POUR IDENTIFIER LES MODULATEURS DE CANAUX CATIONIQUES $i(PARA)
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
WO2002041915A1 (fr) * 2000-11-22 2002-05-30 Nanning Maple Leaf Pharmaceutical Co., Ltd. Composition de compose bloquant les canaux sodiques
EP1930027A3 (fr) * 2000-11-22 2008-06-18 Nanning Maple Leaf Pharmaceutical Co., Ltd. Composition de compose bloquant les canaux sodiques
US20100075992A1 (en) * 2004-09-22 2010-03-25 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain
US20100048592A1 (en) * 2005-08-25 2010-02-25 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the management of musculoskeletal pain
US20100215771A1 (en) * 2006-03-27 2010-08-26 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
US9018222B2 (en) 2006-03-27 2015-04-28 Wex Medical Limited Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
US10149852B2 (en) 2006-03-27 2018-12-11 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
US10624896B2 (en) 2006-03-27 2020-04-21 Wex Medical Limited Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
US11419873B2 (en) 2006-03-27 2022-08-23 Wex Medical Limited Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy

Also Published As

Publication number Publication date
ES427164A1 (es) 1976-10-01
BE816214A (fr) 1974-12-12
AU6993474A (en) 1975-12-11
FR2240735A1 (fr) 1975-03-14
ATA484974A (de) 1976-07-15
CA1027863A (fr) 1978-03-14
DD115035A5 (fr) 1975-09-12
DE2427732A1 (de) 1975-02-27
FR2240735B1 (fr) 1978-07-28
AT335616B (de) 1977-03-25
LU70304A1 (fr) 1976-04-13
JPS5048112A (fr) 1975-04-30
ZA743765B (en) 1975-06-25
IE39410L (en) 1975-02-14
GB1453343A (en) 1976-10-20
IE39410B1 (en) 1978-09-27
NL7407853A (nl) 1975-02-18

Similar Documents

Publication Publication Date Title
Salmons et al. The influence of activity on some contractile characteristics of mammalian fast and slow muscles
Friedenwald et al. The effects of excitement, of epinephrine and of sympathectomy on the mitotic activity of the corneal epithelium in rats
Winter et al. The effect of cortisone, desoxycorticosterone, and adrenocorticotrophic hormone upon the responses of animals to analgesic drugs
Dews et al. The antihistamine substance 2786 RP
Dickson et al. Botulism. Studies on the manner in which the toxin of clostridium botulinum acts upon the body: I. The effect upon the autonomic nervous system.
Langley et al. The physiological action of physostigmine and its action on denervated skeletal muscle
Camras et al. The pathophysiological effects of nitrogen mustard on the rabbit eye. II. The inhibition of the initial hypertensive phase by capsaicin and the apparent role of substance P.
US3898339A (en) Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin
DE69631656T2 (de) Debromhymenialdisin und verwandte verbindungen zur behandlung von osteoarthritis
JP2008533140A (ja) 術後鎮痛剤の低減
JP2003505419A (ja) ケトチフェンを含む眼用組成物
Dahlen et al. A repeated dose-response study of methazolamide in glaucoma
Theobald Jr The effect of arylazido aminopropionyl ATP on atropine resistant contractions of the cat urinary bladder
US20210145850A1 (en) Composition, for osteoarthritis treatment, comprising hydrophilized sulfasalazine and hyaluronic acid and method for preparing same
JPH064534B2 (ja) 長期間の疼痛緩和をもたらす配合剤
AU2020103417A4 (en) Preparation of TN14003 Thermo-sensitive Gel for Treatment of Osteoarthritis by Intraarticular Injection
Olivier et al. Dose related effects of 6-OHDA on rabbit retinal dopamine concentrations and ERG B-wave amplitudes
US3892847A (en) Spinal anesthesia using small amount of saxitoxin
US20080275129A1 (en) Methods and Pharmaceutical Compositions for the Treatment of Neurological Damage
CN114146086A (zh) 维替泊芬在制备抗癌性疼痛的药物中的应用
RU2000101091A (ru) Способ лечения дистрофических заболеваний сетчатки и зрительного нерва
Holmstedt et al. PHARMACOLOGICAL PROPERTIES OF ββ‐DIMETHYL‐ACRYLOYLCHOLINE AND SOME OTHER β‐SUBSTITUTED ACRYLOYLCHOLINES
Paton et al. The ganglion blocking action of procainamide
Haaskjold et al. Use of collagen shields in cataract surgery
Rockhold et al. Methcathinone intoxication in the rat: abrogation by dextrorphan